Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00503490 · ClinicalTrials.gov registry record · Phase 1

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

A Phase 1 study of Cystic Fibrosis, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
14
Study locations

NCT00503490: Completed Phase 1 study of Cystic Fibrosis, sponsored by Amgen.

NCT00503490 is a Phase 1 study of Cystic Fibrosis that has completed, run by Amgen. The registered enrollment target is 40 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00503490, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
14
Study locations

Study Summary

Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms and reduce the emergence of resistant bacteria.

Conditions Studied

Cystic Fibrosis

Interventions

  • DRUG placebo
  • DRUG MP-376 (Levofloxacin solution for Inhalation)

Study Locations (14)

California

  • - La Jolla
  • - Los Angeles
  • - Palo Alto

New York

  • - Albany
  • - New Hyde Park

South Carolina

  • - Charleston
  • - Charleston

Florida

  • - Orlando

Michigan

  • - Kalamazoo

Nebraska

  • - Omaha

Ohio

  • - Columbus

Oklahoma

  • - Oklahoma City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2007-06
Est. Completion 2007-12
Phase Phase 1
Amgen

558 total trials

What the finished NCT00503490 record still lists

NCT00503490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00503490 lists 14 locations in 10 states (California, New York, South Carolina).

Frequently Asked Questions

What is clinical trial NCT00503490 about?

NCT00503490 is a clinical study titled "Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis". Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in...

What is the current status of trial NCT00503490?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-06. Estimated completion is 2007-12.

What conditions does trial NCT00503490 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT00503490?

The interventions under investigation include: placebo (DRUG), MP-376 (Levofloxacin solution for Inhalation) (DRUG).

Who is sponsoring clinical trial NCT00503490?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00503490 being conducted?

This trial has 14 study locations across California, Florida, Michigan, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00503490's enrollment target sits among peer trials

40 100th of 169 higher than 66 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00503490, the US trial registry maintained by the National Library of Medicine. NCT00503490 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.